Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.914 |
High Similarity |
NPD3924 |
Approved |
0.914 |
High Similarity |
NPD3922 |
Approved |
0.914 |
High Similarity |
NPD3923 |
Approved |
0.914 |
High Similarity |
NPD3921 |
Approved |
0.8794 |
High Similarity |
NPD3816 |
Phase 1 |
0.8794 |
High Similarity |
NPD3815 |
Phase 1 |
0.8548 |
High Similarity |
NPD3920 |
Phase 2 |
0.8429 |
Intermediate Similarity |
NPD6257 |
Clinical (unspecified phase) |
0.8351 |
Intermediate Similarity |
NPD6569 |
Phase 2 |
0.8263 |
Intermediate Similarity |
NPD7414 |
Clinical (unspecified phase) |
0.8233 |
Intermediate Similarity |
NPD6494 |
Phase 2 |
0.8182 |
Intermediate Similarity |
NPD3763 |
Approved |
0.8135 |
Intermediate Similarity |
NPD4889 |
Approved |
0.8088 |
Intermediate Similarity |
NPD7222 |
Phase 2 |
0.8082 |
Intermediate Similarity |
NPD7729 |
Clinical (unspecified phase) |
0.8049 |
Intermediate Similarity |
NPD5863 |
Clinical (unspecified phase) |
0.797 |
Intermediate Similarity |
NPD6219 |
Discontinued |
0.7926 |
Intermediate Similarity |
NPD8052 |
Clinical (unspecified phase) |
0.7906 |
Intermediate Similarity |
NPD1923 |
Clinical (unspecified phase) |
0.79 |
Intermediate Similarity |
NPD6861 |
Clinical (unspecified phase) |
0.7892 |
Intermediate Similarity |
NPD6477 |
Clinical (unspecified phase) |
0.787 |
Intermediate Similarity |
NPD7674 |
Phase 3 |
0.787 |
Intermediate Similarity |
NPD7676 |
Clinical (unspecified phase) |
0.787 |
Intermediate Similarity |
NPD8091 |
Phase 3 |
0.787 |
Intermediate Similarity |
NPD7675 |
Phase 3 |
0.7864 |
Intermediate Similarity |
NPD6963 |
Approved |
0.7864 |
Intermediate Similarity |
NPD6964 |
Approved |
0.7861 |
Intermediate Similarity |
NPD3477 |
Phase 2 |
0.7861 |
Intermediate Similarity |
NPD3478 |
Clinical (unspecified phase) |
0.7851 |
Intermediate Similarity |
NPD7859 |
Phase 2 |
0.785 |
Intermediate Similarity |
NPD4551 |
Phase 2 |
0.7826 |
Intermediate Similarity |
NPD7452 |
Approved |
0.7826 |
Intermediate Similarity |
NPD7453 |
Approved |
0.7822 |
Intermediate Similarity |
NPD6230 |
Discontinued |
0.782 |
Intermediate Similarity |
NPD6140 |
Clinical (unspecified phase) |
0.7811 |
Intermediate Similarity |
NPD4418 |
Discontinued |
0.781 |
Intermediate Similarity |
NPD7069 |
Discontinued |
0.7789 |
Intermediate Similarity |
NPD6872 |
Clinical (unspecified phase) |
0.7788 |
Intermediate Similarity |
NPD5658 |
Approved |
0.7742 |
Intermediate Similarity |
NPD7719 |
Discontinued |
0.7721 |
Intermediate Similarity |
NPD5070 |
Clinical (unspecified phase) |
0.7707 |
Intermediate Similarity |
NPD4396 |
Clinical (unspecified phase) |
0.7678 |
Intermediate Similarity |
NPD4131 |
Phase 3 |
0.7658 |
Intermediate Similarity |
NPD7558 |
Phase 2 |
0.7644 |
Intermediate Similarity |
NPD31 |
Approved |
0.7644 |
Intermediate Similarity |
NPD3397 |
Phase 2 |
0.7644 |
Intermediate Similarity |
NPD32 |
Approved |
0.7644 |
Intermediate Similarity |
NPD4036 |
Approved |
0.7644 |
Intermediate Similarity |
NPD4034 |
Approved |
0.7644 |
Intermediate Similarity |
NPD4035 |
Approved |
0.7644 |
Intermediate Similarity |
NPD4037 |
Approved |
0.7644 |
Intermediate Similarity |
NPD4039 |
Approved |
0.7644 |
Intermediate Similarity |
NPD4122 |
Approved |
0.7644 |
Intermediate Similarity |
NPD4038 |
Approved |
0.7644 |
Intermediate Similarity |
NPD4033 |
Approved |
0.7628 |
Intermediate Similarity |
NPD6568 |
Discontinued |
0.7626 |
Intermediate Similarity |
NPD7426 |
Phase 1 |
0.7617 |
Intermediate Similarity |
NPD5612 |
Discontinued |
0.7574 |
Intermediate Similarity |
NPD2334 |
Discontinued |
0.7564 |
Intermediate Similarity |
NPD7169 |
Suspended |
0.756 |
Intermediate Similarity |
NPD4795 |
Phase 2 |
0.7555 |
Intermediate Similarity |
NPD8100 |
Phase 3 |
0.7551 |
Intermediate Similarity |
NPD1032 |
Phase 2 |
0.7525 |
Intermediate Similarity |
NPD3386 |
Phase 2 |
0.7524 |
Intermediate Similarity |
NPD5601 |
Phase 2 |
0.7524 |
Intermediate Similarity |
NPD5530 |
Phase 1 |
0.7512 |
Intermediate Similarity |
NPD1034 |
Phase 3 |
0.7512 |
Intermediate Similarity |
NPD1033 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD2782 |
Approved |
0.75 |
Intermediate Similarity |
NPD2780 |
Approved |
0.7463 |
Intermediate Similarity |
NPD3395 |
Approved |
0.7463 |
Intermediate Similarity |
NPD4375 |
Approved |
0.7463 |
Intermediate Similarity |
NPD3396 |
Approved |
0.7457 |
Intermediate Similarity |
NPD8101 |
Phase 3 |
0.7453 |
Intermediate Similarity |
NPD2739 |
Clinical (unspecified phase) |
0.7449 |
Intermediate Similarity |
NPD5602 |
Clinical (unspecified phase) |
0.7443 |
Intermediate Similarity |
NPD5147 |
Discontinued |
0.7442 |
Intermediate Similarity |
NPD7571 |
Clinical (unspecified phase) |
0.7438 |
Intermediate Similarity |
NPD8063 |
Discontinued |
0.7437 |
Intermediate Similarity |
NPD4203 |
Approved |
0.7437 |
Intermediate Similarity |
NPD4204 |
Approved |
0.7432 |
Intermediate Similarity |
NPD6553 |
Clinical (unspecified phase) |
0.7424 |
Intermediate Similarity |
NPD4875 |
Phase 3 |
0.7424 |
Intermediate Similarity |
NPD4876 |
Phase 3 |
0.7423 |
Intermediate Similarity |
NPD2781 |
Approved |
0.7415 |
Intermediate Similarity |
NPD1038 |
Approved |
0.7415 |
Intermediate Similarity |
NPD1304 |
Clinical (unspecified phase) |
0.7414 |
Intermediate Similarity |
NPD8350 |
Clinical (unspecified phase) |
0.7412 |
Intermediate Similarity |
NPD7885 |
Phase 2 |
0.7412 |
Intermediate Similarity |
NPD7886 |
Phase 2 |
0.7407 |
Intermediate Similarity |
NPD5902 |
Approved |
0.7407 |
Intermediate Similarity |
NPD5903 |
Approved |
0.7404 |
Intermediate Similarity |
NPD3825 |
Phase 3 |
0.7404 |
Intermediate Similarity |
NPD8442 |
Discontinued |
0.7397 |
Intermediate Similarity |
NPD7678 |
Clinical (unspecified phase) |
0.7397 |
Intermediate Similarity |
NPD5930 |
Phase 3 |
0.7391 |
Intermediate Similarity |
NPD7620 |
Phase 2 |
0.7379 |
Intermediate Similarity |
NPD6491 |
Clinical (unspecified phase) |
0.7378 |
Intermediate Similarity |
NPD4885 |
Approved |
0.7376 |
Intermediate Similarity |
NPD4920 |
Clinical (unspecified phase) |
0.7376 |
Intermediate Similarity |
NPD4921 |
Phase 3 |
0.7376 |
Intermediate Similarity |
NPD4919 |
Phase 3 |
0.7374 |
Intermediate Similarity |
NPD4071 |
Approved |
0.7374 |
Intermediate Similarity |
NPD4072 |
Approved |
0.7371 |
Intermediate Similarity |
NPD7672 |
Approved |
0.7371 |
Intermediate Similarity |
NPD5528 |
Clinical (unspecified phase) |
0.7371 |
Intermediate Similarity |
NPD7671 |
Approved |
0.7371 |
Intermediate Similarity |
NPD5529 |
Phase 1 |
0.7366 |
Intermediate Similarity |
NPD4372 |
Phase 1 |
0.7362 |
Intermediate Similarity |
NPD4926 |
Clinical (unspecified phase) |
0.7352 |
Intermediate Similarity |
NPD6501 |
Approved |
0.7352 |
Intermediate Similarity |
NPD6500 |
Approved |
0.7347 |
Intermediate Similarity |
NPD1078 |
Clinical (unspecified phase) |
0.733 |
Intermediate Similarity |
NPD6361 |
Phase 2 |
0.7327 |
Intermediate Similarity |
NPD7424 |
Clinical (unspecified phase) |
0.7323 |
Intermediate Similarity |
NPD8251 |
Approved |
0.7323 |
Intermediate Similarity |
NPD8252 |
Approved |
0.7323 |
Intermediate Similarity |
NPD8099 |
Discontinued |
0.7308 |
Intermediate Similarity |
NPD6769 |
Clinical (unspecified phase) |
0.7306 |
Intermediate Similarity |
NPD7395 |
Discontinued |
0.7304 |
Intermediate Similarity |
NPD4021 |
Phase 2 |
0.7302 |
Intermediate Similarity |
NPD6262 |
Clinical (unspecified phase) |
0.7291 |
Intermediate Similarity |
NPD2917 |
Approved |
0.7286 |
Intermediate Similarity |
NPD5751 |
Clinical (unspecified phase) |
0.7286 |
Intermediate Similarity |
NPD1739 |
Approved |
0.7286 |
Intermediate Similarity |
NPD1740 |
Approved |
0.7286 |
Intermediate Similarity |
NPD8156 |
Discontinued |
0.7277 |
Intermediate Similarity |
NPD5083 |
Clinical (unspecified phase) |
0.7277 |
Intermediate Similarity |
NPD2060 |
Approved |
0.726 |
Intermediate Similarity |
NPD6550 |
Discontinued |
0.726 |
Intermediate Similarity |
NPD7823 |
Clinical (unspecified phase) |
0.7257 |
Intermediate Similarity |
NPD4995 |
Approved |
0.7257 |
Intermediate Similarity |
NPD4996 |
Approved |
0.7252 |
Intermediate Similarity |
NPD1856 |
Discontinued |
0.7251 |
Intermediate Similarity |
NPD6592 |
Clinical (unspecified phase) |
0.7244 |
Intermediate Similarity |
NPD7710 |
Clinical (unspecified phase) |
0.7244 |
Intermediate Similarity |
NPD7555 |
Discontinued |
0.7243 |
Intermediate Similarity |
NPD5429 |
Discontinued |
0.7241 |
Intermediate Similarity |
NPD6344 |
Clinical (unspecified phase) |
0.724 |
Intermediate Similarity |
NPD2581 |
Approved |
0.724 |
Intermediate Similarity |
NPD2582 |
Approved |
0.7238 |
Intermediate Similarity |
NPD3541 |
Clinical (unspecified phase) |
0.7238 |
Intermediate Similarity |
NPD4118 |
Clinical (unspecified phase) |
0.723 |
Intermediate Similarity |
NPD3946 |
Clinical (unspecified phase) |
0.7228 |
Intermediate Similarity |
NPD5522 |
Clinical (unspecified phase) |
0.7225 |
Intermediate Similarity |
NPD7948 |
Phase 1 |
0.7214 |
Intermediate Similarity |
NPD2599 |
Approved |
0.7214 |
Intermediate Similarity |
NPD2601 |
Approved |
0.7214 |
Intermediate Similarity |
NPD2600 |
Approved |
0.7212 |
Intermediate Similarity |
NPD4925 |
Approved |
0.7212 |
Intermediate Similarity |
NPD6590 |
Discontinued |
0.7203 |
Intermediate Similarity |
NPD6503 |
Clinical (unspecified phase) |
0.7196 |
Intermediate Similarity |
NPD8403 |
Phase 1 |
0.7193 |
Intermediate Similarity |
NPD6741 |
Clinical (unspecified phase) |
0.719 |
Intermediate Similarity |
NPD7889 |
Clinical (unspecified phase) |
0.7189 |
Intermediate Similarity |
NPD4502 |
Phase 2 |
0.7186 |
Intermediate Similarity |
NPD7025 |
Clinical (unspecified phase) |
0.7168 |
Intermediate Similarity |
NPD5559 |
Phase 2 |
0.7167 |
Intermediate Similarity |
NPD7955 |
Approved |
0.7167 |
Intermediate Similarity |
NPD7956 |
Approved |
0.7162 |
Intermediate Similarity |
NPD7807 |
Clinical (unspecified phase) |
0.7161 |
Intermediate Similarity |
NPD6244 |
Phase 3 |
0.7161 |
Intermediate Similarity |
NPD6525 |
Clinical (unspecified phase) |
0.7161 |
Intermediate Similarity |
NPD6243 |
Phase 3 |
0.7156 |
Intermediate Similarity |
NPD4927 |
Discontinued |
0.7155 |
Intermediate Similarity |
NPD8049 |
Phase 2 |
0.7149 |
Intermediate Similarity |
NPD8109 |
Clinical (unspecified phase) |
0.7149 |
Intermediate Similarity |
NPD7705 |
Clinical (unspecified phase) |
0.7143 |
Intermediate Similarity |
NPD2952 |
Discontinued |
0.7137 |
Intermediate Similarity |
NPD7567 |
Approved |
0.7137 |
Intermediate Similarity |
NPD8512 |
Phase 3 |
0.7137 |
Intermediate Similarity |
NPD7708 |
Approved |
0.7136 |
Intermediate Similarity |
NPD6147 |
Clinical (unspecified phase) |
0.7136 |
Intermediate Similarity |
NPD6208 |
Discontinued |
0.713 |
Intermediate Similarity |
NPD4881 |
Clinical (unspecified phase) |
0.7129 |
Intermediate Similarity |
NPD1602 |
Discontinued |
0.7129 |
Intermediate Similarity |
NPD3324 |
Clinical (unspecified phase) |
0.7122 |
Intermediate Similarity |
NPD5256 |
Discontinued |
0.7121 |
Intermediate Similarity |
NPD4724 |
Clinical (unspecified phase) |
0.7119 |
Intermediate Similarity |
NPD5007 |
Approved |
0.7117 |
Intermediate Similarity |
NPD3402 |
Phase 1 |
0.7112 |
Intermediate Similarity |
NPD8016 |
Phase 3 |
0.7112 |
Intermediate Similarity |
NPD5905 |
Phase 1 |
0.7112 |
Intermediate Similarity |
NPD8017 |
Clinical (unspecified phase) |
0.711 |
Intermediate Similarity |
NPD5067 |
Phase 2 |
0.711 |
Intermediate Similarity |
NPD5066 |
Phase 2 |
0.7103 |
Intermediate Similarity |
NPD6991 |
Approved |
0.7101 |
Intermediate Similarity |
NPD6281 |
Approved |
0.7098 |
Intermediate Similarity |
NPD1954 |
Phase 1 |
0.7095 |
Intermediate Similarity |
NPD2482 |
Clinical (unspecified phase) |
0.7091 |
Intermediate Similarity |
NPD6528 |
Phase 1 |
0.7089 |
Intermediate Similarity |
NPD5437 |
Clinical (unspecified phase) |
0.7085 |
Intermediate Similarity |
NPD6242 |
Discontinued |
0.7083 |
Intermediate Similarity |
NPD1392 |
Approved |
0.7079 |
Intermediate Similarity |
NPD1620 |
Clinical (unspecified phase) |
0.7075 |
Intermediate Similarity |
NPD3837 |
Clinical (unspecified phase) |
0.7073 |
Intermediate Similarity |
NPD8054 |
Approved |
0.7073 |
Intermediate Similarity |
NPD8053 |
Approved |
0.7067 |
Intermediate Similarity |
NPD4148 |
Approved |
0.7064
|
Intermediate Similarity |
NPD5483 |
Clinical (unspecified phase) |